IDEXX delivered strong Q1 growth on the back of recurring diagnostics, premium instrument placements, and high customer retention. The stock still looks expensive, but the installed-base flywheel and raised 2026 guidance support a Buy.
IDEXX Laboratories (IDXX) merits a Buy rating for a medium-term, moderate-risk portfolio because its core veterinary diagnostics platform combines 11% organic CAG Diagnostics recurring revenue growth, a 12% increase in the premium instrument installed base, and customer retention in the high 90s. Q1 2026 revenue rose 14% reported to $1.14B, while comparable EPS increased 15% to $3.47. Management also raised 2026 revenue guidance to $4.68B-$4.76B and EPS guidance to $14.45-$14.90.
The business has the economics of an installed-base flywheel. IDEXX places analyzers and software in veterinary practices, then generates recurring revenue from consumables, reference laboratory testing, software, and services. The model produced $1.05B of free cash flow in 2025, equal to a 2.9% FCF yield on the stated valuation data. The tradeoff is price: at the $558.80 per-share level recorded on July 30, 2026, IDXX trades at 41.8x trailing earnings, 37.9x forward earnings, a 3.6 PEG ratio, and 10.1x enterprise value to revenue.
The thesis therefore rests on execution rather than multiple expansion. Cancer Dx, inVue Dx, F&A analysis, cloud-native practice software, and diagnostic imaging provide identifiable growth products, while U.S. clinical visits declined 1% in Q1 and management expects a 1.5% decline for 2026. The stock can compound if diagnostic utilization continues to rise despite softer visits, but the valuation leaves less room for an execution stumble.
IDEXX Laboratories was incorporated in 1983 and is headquartered in Westbrook, Maine. The company had approximately 11,000 employees and operates across companion animal diagnostics, water quality products, and livestock, poultry, and dairy testing. Its offerings include point-of-care analyzers, consumables, reference laboratory services, rapid assays, veterinary software, diagnostic imaging, telemedicine, and water microbiology tests.
IDEXX sells through direct marketing, customer service, sales, technical service groups, independent distributors, and resellers. Its international footprint matters because management estimates the global companion animal diagnostics opportunity at approximately $45B, with about two-thirds outside the U.S. Q1 international CAG Diagnostics recurring revenue grew 12% organically, matching the pace of the U.S. business despite similar pressure on veterinary visits.
CAG delivered the strongest Q1 performance. Revenue increased 12% organically, supported by 11% organic growth in Diagnostics recurring revenue and 28% organic growth in instrument revenue. VetLab consumables grew 15% organically, while global reference laboratory revenue increased 10% organically. Premium instrument placements reached 4,650 units, up 12% year over year, including 1,100 inVue Dx analyzers.
The recurring engine showed strength across both geography and modality. U.S. CAG Diagnostics recurring revenue grew nearly 11% organically, while international revenue grew 12%. The installed base of premium instruments increased 12% year over year. Rapid assay revenue was flat organically because customers shifted pancreatic lipase testing to the Catalyst platform, creating an estimated 2% headwind to Q1 growth in that product category.
Veterinary software and diagnostic imaging revenue increased 11% organically. Cloud-native practice management software placements grew double digits, and diagnostic imaging produced approximately 330 installations in Q1 after the launch of ImageVue DR50 PLUS. Water revenue increased 7% organically, while Livestock, Poultry and Dairy revenue also increased 7% organically. These smaller segments add diversification, although their growth rates were below the main CAG recurring revenue engine.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The flagship economic product is the IDEXX VetLab ecosystem, particularly the Catalyst family of analyzers and associated consumables. IDEXX reported nearly 79,000 Catalyst customers in Q1 2026 and added more than 1,000 new and competitive customers during the quarter. Each placement expands the installed base that supports recurring consumable revenue, while the expanded Catalyst menu includes pancreatic lipase and cortisol testing.
inVue Dx is the most important newer platform layered onto that ecosystem. IDEXX placed 1,100 inVue Dx analyzers in Q1 and maintained a full-year target of 5,500 placements. Management reported that the premium installed base grew 12% year over year and that inVue Dx utilization was tracking to internal recurring revenue assumptions. The platform supports ear cytology and blood morphology, with monthly software updates designed to improve performance and time to results.
The product economics are visible in the revenue mix. CAG instrument revenue grew 28% organically, while VetLab consumables grew 15% organically. The second-quarter outlook includes a decline in CAG instrument revenue as IDEXX begins to lap significant inVue Dx placements from 2025, but the installed base and recurring consumables provide a more durable earnings contribution than a single equipment sale.
IDEXX's advantage is the combination of diagnostic hardware, laboratory services, software, clinical support, and data. The company's 2025 10-K identifies time to result, ease of use, menu breadth, accuracy, software integration, customer service, and installed-base economics as competitive factors. Q1 customer retention remained in the high 90s, a measurable sign that the integrated workflow has value to veterinary practices.
Cancer Dx is extending that advantage into veterinary oncology. More than 7,500 practices had ordered the product by Q1, and approximately 20% of Cancer Dx customers were non-primary IDEXX reference laboratory accounts. The company also launched Cancer Dx for lymphoma and other applications in Europe and Australia, expanding the product's geographic reach and its role in both wellness panels and ongoing monitoring.
F&A analysis on inVue Dx adds an AI-supported workflow for evaluating lumps and bumps during the patient visit, with optional expert pathologist review. Management described early customer response as very encouraging and said utilization was tracking to planning assumptions. The broader innovation pipeline also includes additional Cancer Dx testing, AI embedded in inVue Dx and ezyVet, and the ImageVue DR50 PLUS imaging system, which management said can use up to 60% lower dose than premium competitors.
Operating execution was strong in Q1. Gross margin reached 63.4%, up 90 basis points, while comparable operating margin expanded 100 basis points. Management said pricing benefits offset inflationary cost pressure, and foreign exchange after hedging had a negligible impact on reported gross margin during the quarter. Full-year 2026 operating margin guidance is 32.1%-32.5%, representing 50-90 basis points of comparable expansion.
Capital requirements remain moderate relative to cash generation. Q1 free cash flow was $234M, and management maintained full-year capital spending guidance of approximately $180M with free cash flow conversion of 85%-95% of net income. The company also repurchased $361M of stock in Q1, contributing to a 2.1% year-over-year reduction in diluted shares outstanding.
The main operating friction appeared in the Water segment, where international growth was affected by supply chain dynamics in the Middle East. The 2025 10-K also describes exposure to foreign-sourced services, variable-rate borrowings, and the risk that hedges will not fully offset currency movements. IDEXX maintains cybersecurity training, phishing tests, third-party risk reviews, incident response procedures, and backup planning under the program described in its February 20, 2026 Form 10-K.
IDEXX is addressing a companion animal diagnostics opportunity that management estimates at approximately $45B globally. About two-thirds of that opportunity lies outside the U.S., while Q1 international CAG Diagnostics recurring revenue grew 12% organically. The geographic split gives IDEXX a long runway for international commercial expansion, especially where diagnostic utilization remains below U.S. levels.
Near-term market conditions are mixed. U.S. same-store clinical visits declined approximately 1% in Q1, with wellness visits down 3% and non-well visits up 0.2%. Management's full-year assumption calls for a 1.5% decline in U.S. clinical visits. At the same time, pets aged five years and older produced positive visit trends, while diagnostic frequency and utilization per visit continued to expand.
The market is shifting toward workflow automation and recurring services. IDEXX's double-digit cloud software growth, AI-supported inVue Dx tools, telemedicine integration, and diagnostic imaging installations place the company inside that shift. The operating evidence is already visible: Q1 CAG Diagnostics recurring revenue grew 11% organically despite the decline in U.S. clinical visits.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
IDEXX serves independent veterinary practices, corporate groups, diagnostic laboratories, livestock and dairy operators, poultry producers, municipalities, and water testing organizations. Within companion animal diagnostics, the strongest customer relationship is with veterinary practices that use IDEXX analyzers, consumables, reference laboratories, software, imaging, and clinical support together.
The customer data supports meaningful workflow dependence. Nearly 79,000 Catalyst customers had access to expanded menu offerings in Q1, and customer retention remained in the high 90s. IDEXX also reported that practices using its software and imaging solutions experienced faster clinical revenue growth and diagnostic usage. That result supports the value proposition of combining medical information with practice productivity tools.
Customer concentration is an important counterweight. The 2025 10-K warns that consolidation among corporate hospital groups and buying organizations can increase purchaser bargaining power. IDEXX's 4% average global net price improvement in Q1 demonstrates pricing execution, but larger customers can eventually pressure contract terms or shift testing toward internal laboratories.
IDEXX's named competitors include Mars-owned Antech Diagnostics and Heska, Zoetis and its Abaxis business, Covetrus, Fujifilm, Arkray, Mindray, BioNote, scil animal care, and Asia Veterinary Diagnostics. Sound-Eklin and other providers compete in diagnostic imaging. The company also competes with corporate hospital chains that operate internal reference laboratories.
IDEXX differentiates through breadth and integration. Its platform spans point-of-care instruments, consumables, reference laboratories, software, imaging, telemedicine, and clinical consultation. Q1 included more than 1,000 new and competitive Catalyst placements, nearly 320 of them in North America, showing that IDEXX continued to win customers even as competitors remained active.
The competitive risk is therefore less about a single rival and more about sustained innovation and purchasing power. The 2025 10-K states that IDEXX must continue introducing analyzers, tests, software, and services to defend its position. The current product cycle supports that effort, but a slower inVue Dx or Cancer Dx adoption curve would weaken the installed-base growth narrative.
Pet healthcare demand is showing both resilience and consumer sensitivity. Management reported a 1% decline in U.S. clinical visits in Q1 and cited consumers making trade-offs around clinic visits, while diagnostic frequency and utilization increased when pets did enter the practice. The positive trend among pets aged five and older provides a specific demographic support for testing demand.
Currency is a material external variable. IDEXX expects foreign exchange to provide approximately 90 basis points of full-year 2026 reported revenue growth under its stated assumptions. Management also quantified the downside: a 1% strengthening of the U.S. dollar would reduce revenue by approximately $12M and EPS by $0.04 for the remainder of the year.
Geopolitical exposure is visible in the Water segment, where Middle East supply chain dynamics affected international growth in Q1. The 2025 10-K also identifies variable-rate debt tied partly to SOFR, foreign currency exposure in the euro, British pound, Canadian dollar, Japanese yen, and Australian dollar, and the possibility that economic or credit-market changes could increase borrowing costs.
Free cash flow reached $1.05B in 2025, but the stock still trades at 41.8x trailing earnings and 10.1x EV/revenue, leaving limited margin for error.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q1 2026 revenue rose 14% to $1.14B and comparable EPS climbed 15% to $3.47, with management lifting full-year revenue and EPS guidance.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management raised 2026 revenue guidance to $4.68B-$4.76B and EPS guidance to $14.45-$14.90 after a quarter of 11% organic recurring diagnostics growth.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At $558.80 per share, IDXX trades at 41.8x trailing earnings, 37.9x forward earnings, and a 3.6 PEG ratio despite durable recurring growth.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Our fair value estimate is $600, with upside supported by the installed-base flywheel but capped by a valuation that already prices in strong execution.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →IDEXX has built one of the stronger recurring-revenue models in veterinary diagnostics. The evidence is concrete: $4.30B of 2025 revenue, $1.05B of free cash flow, 63.4% Q1 gross margin, 11% organic CAG Diagnostics recurring revenue growth, and a 12% increase in the premium instrument installed base. Cancer Dx, inVue Dx, AI-supported F&A analysis, cloud software, and imaging provide multiple avenues for continued platform expansion.
The investment is not risk-free. U.S. clinical visits declined 1% in Q1, debt rose from 2024 levels, Water operations encountered Middle East supply chain pressure, and the valuation remains demanding. Yet management raised 2026 guidance, the company has delivered seven consecutive reported earnings beats in the available history, and analyst estimates extend to $26.10 of EPS in 2030. That combination supports a measured Buy, with the strongest risk-reward reserved for prices below the stated $600 fair value estimate.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
IDEXX Laboratories, Inc. (IDXX) gains after a Q2 beat, but the real story is in the details: recurring diagnostics growth, margin expansion, and a raised 2026 outlook. This deep-dive breaks down segment performance, pricing, instrument trends, and what the guidance implies for the stock.
IDEXX Laboratories, Inc. (IDXX) gains 3.7% after reporting earnings beats, as investors react positively to stronger-than-expected results and improved outlook.
U.S. factory orders slipped in June, missing forecasts and signaling softer manufacturing momentum beyond transportation. Still, strong core capital-goods demand tied to AI investment helped offset the weakness, while the ISM index stayed in expansion territory and kept recession fears in check.